Madrigal Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
MDGL
CUSIP
558868105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 558868105 since 12/18/2024, newest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A Amendment 4 4.6% 7/29/2026
Event 6/30/2026
Janus Henderson Group PLC 13G/A Amendment 9 8.8% 5/15/2026
Event 3/31/2026
Paulson & Co. Inc. 13G/A Amendment 4 6.1% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/27/2026
Event 3/13/2026
Janus Henderson Group PLC 13G/A Amendment 8 7.0% 2/17/2026
Event 12/31/2025
Paulson & Co. Inc. 13G/A Amendment 3 7.5% 2/17/2026
Event 12/31/2025
Taub Rebecca 13D/A Amendment 2 7.8% 12/12/2025
Event 12/10/2025
Friedman Paul A 13D/A Amendment 2 7.8% 12/12/2025
Event 12/10/2025
Taub Rebecca 13D/A Amendment 2 7.8% 12/12/2025
Event 12/10/2025
Friedman Paul A 13D/A Amendment 2 7.8% 12/12/2025
Event 12/10/2025
Janus Henderson Group PLC 13G/A Amendment 7 8.3% 11/14/2025
Event 9/30/2025
Janus Henderson Group PLC 13G/A Amendment 6 9.9% 8/14/2025
Event 6/30/2025
Janus Henderson Group PLC 13G/A Amendment 5 10.0% 5/14/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 4 10.1% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 1.50 k $757 k
2026 Q2 443 32.9 M $12.7 B
2026 Q1 411 23.8 M $12.4 B
2025 Q4 421 23.6 M $13.7 B
2025 Q3 387 23.4 M $10.7 B
2025 Q2 338 23.7 M $7.17 B
2025 Q1 353 23.7 M $7.85 B
2024 Q4 323 23.0 M $7.08 B
2024 Q3 291 22.8 M $4.79 B
2024 Q2 297 23.1 M $6.49 B
2024 Q1 317 21.8 M $5.83 B
2023 Q4 262 20.1 M $4.65 B
2023 Q3 235 17.4 M $2.54 B
2023 Q2 241 14.9 M $3.45 B
2023 Q1 256 14.0 M $3.38 B
2022 Q4 226 14.8 M $4.28 B
2022 Q3 157 11.8 M $770 M
2022 Q2 154 12.0 M $858 M
2022 Q1 154 12.3 M $1.20 B
2021 Q4 163 12.1 M $1.03 B
2021 Q3 146 11.0 M $876 M
2021 Q2 162 11.2 M $1.09 B
2021 Q1 149 12.2 M $1.43 B
2020 Q4 149 12.5 M $1.39 B
2020 Q3 143 11.6 M $1.38 B
2020 Q2 140 11.3 M $1.28 B
2020 Q1 118 11.1 M $741 M
2019 Q4 134 10.6 M $966 M
2019 Q3 123 9.64 M $831 M
2019 Q2 145 9.79 M $1.03 B
2019 Q1 159 9.63 M $1.21 B
2018 Q4 156 9.07 M $1.02 B
2018 Q3 178 8.78 M $1.88 B
2018 Q2 158 8.16 M $2.28 B
2018 Q1 101 6.38 M $745 M
2017 Q4 92 5.13 M $471 M
2017 Q3 53 2.67 M $120 M
2017 Q2 42 2.05 M $33.3 M
2017 Q1 33 1.53 M $23.6 M
2016 Q4 32 1.35 M $20.1 M
2016 Q3 32 1.01 M $12.8 M
2016 Q2 1 79.6 k $21.0 k